Insmed is a global biopharmaceutical company focused on the needs of patients with rare diseases. Headquartered in Bridgewater, NJ, Insmed is a dynamic and rapidly growing company with a strong pipeline of drug candidates. Patients who suffer from rare diseases, such as nontuberculous mycobacteria (NTM) lung disease and pulmonary arterial hypertension (PAH), face multiple hurdles in finding effective treatments. Insmed is addressing the critical, unmet needs of these orphan patient populations. The company’s lead product candidate is an inhaled antibiotic that is in late-stage clinical development for serious lung infections caused by NTM. There are currently no approved therapies in the United States or European Union for NTM lung disease. “Insmed is a team of talented and motivated professionals who are dedicated to making a difference in the lives of patients with rare diseases, said Will Lewis, president and CEO at Insmed. “Patients are at the center of everything we do and each of us brings a personal passion for advancing innovative therapies that can transform the lives of patients with rare diseases around the world.”
The company is also developing INS1009, a nebulized treprostinil prodrug for the treatment of PAH. Insmed’s innovative focus is on the convenient dosing regimen, enhanced drug delivery, and lower systemic drug exposure which exemplifies its priority to improve patient comfort and care.
Company Growth (employees)